Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.
Explore AstraZeneca's 6-K filing detailing Imfinzi's Phase III MATTERHORN trial results, showing significant improvements in event-free survival for gastric cancer patients.
AstraZeneca's Imfinzi receives EU approval as the first immunotherapy for LS-SCLC, showing significant survival benefits. This landmark decision highlights advancements in cancer care.
Discover AstraZeneca's groundbreaking approval of Imfinzi for muscle-invasive bladder cancer, backed by clinical trials showing improved survival rates and reduced recurrence.
Explore Estrella Immunopharma's February 2025 8-K filing, detailing stock info, warrants, and key financial insights for investors.
Explore Citius Oncology's Q4 2024 financial performance, including a $6.6M net loss, cash struggles, and reliance on parent funding, all crucial for investor decisions.
Explore Sonnet BioTherapeutics' Q4 2024 financials, highlighting cash position, R&D losses, and strategic partnerships in oncology. Key insights and investment recommendations included.
Explore Replimune Group, Inc.'s Q4 2024 financial report. Key insights on losses, cash management, and clinical trial outcomes suggest a 'Hold' stock recommendation.
Explore the latest 8-K report from Vaxart, Inc. (Ticker: VXRT) detailing significant corporate events as of December 20, 2024. Stay informed on their NASDAQ activities.
Discover key insights from Portage Biotech Inc.'s Form 6-K filed on Dec 17, 2024, detailing their LOI with Immunova for iOx Therapeutics acquisition, signaling potential growth.
Explore AC Immune SA's December 2024 report detailing key executive promotions and departures, reflecting its drive in AI and immunotherapy advancements.